Focusing on intestinal tumours, we assessed the prognostic value of GNL and further compared it with other clinically relevant gastric cancer biomarkers, including E-cadherin, p53, MSI, and the cancer-associated glycans sTn and sLeA. The gene discussed is TP53; the disease is cancer.